伊布替尼对套细胞淋巴瘤中的自身免疫性溶血性贫血有效。
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma.
作者信息
Galinier Aliénor, Delwail Vincent, Puyade Mathieu
机构信息
CHU de Poitiers, Service d'Onco-Hématologie et Thérapie Cellulaire, Poitiers, France.
出版信息
Case Rep Oncol. 2017 Jan 27;10(1):127-129. doi: 10.1159/000456002. eCollection 2017 Jan-Apr.
Abstract
Autoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and consequently the production of autoantibodies. We report a case of MCL with AIHA in which this form of anaemia was not controlled with the usual chemotherapy. Ibrutinib was used when MCL with AIHA relapsed, and it allowed rapid remission of AIHA and rapid discontinuation of steroid therapy.
摘要
套细胞淋巴瘤（MCL）中的自身免疫性溶血性贫血（AIHA）是一种罕见但危及生命的并发症。迄今为止，尚无关于MCL中AIHA治疗的相关数据。已被批准用于复发/难治性MCL的伊布替尼是一种免疫调节药物，可抑制Th2激活，从而抑制自身抗体的产生。我们报告一例MCL合并AIHA的病例，该类型贫血采用常规化疗无法得到控制。当MCL合并AIHA复发时使用了伊布替尼，其使AIHA迅速缓解，并使类固醇治疗迅速停用。
相似文献
1
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma.
Case Rep Oncol. 2017 Jan 27;10(1):127-129. doi: 10.1159/000456002. eCollection 2017 Jan-Apr.
2
Autoimmune haemolytic anaemia associated with mantle cell lymphoma.
Int J Hematol. 2010 Mar;91(2):322-5. doi: 10.1007/s12185-009-0489-9.
3
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease.
Hematol Oncol. 2017 Mar;35(1):135-137. doi: 10.1002/hon.2241. Epub 2015 Jun 15.
4
Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma.
Hematology. 2007 Apr;12(2):159-62. doi: 10.1080/110245330601111466.
5
Metabolomic profile in patients with primary warm autoimmune haemolytic anaemia.
Br J Haematol. 2023 Apr;201(1):140-149. doi: 10.1111/bjh.18584. Epub 2022 Dec 9.
6
Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review.
Clin Case Rep. 2019 Sep 3;7(10):1957-1961. doi: 10.1002/ccr3.2257. eCollection 2019 Oct.
7
A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome.
Br J Haematol. 2024 Mar;204(3):1082-1085. doi: 10.1111/bjh.19146. Epub 2023 Nov 6.
8
[Treatment for mantle cell lymphoma].
Rinsho Ketsueki. 2017;58(10):2026-2032. doi: 10.11406/rinketsu.58.2026.
9
The co-existence of pure red cell aplasia and autoimmune haemolytic anaemia in a child with malignant lymphoma.
Malays J Med Sci. 2005 Jul;12(2):56-9.
10
Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman.
Eur J Haematol. 2003 Jan;70(1):60-3. doi: 10.1034/j.1600-0609.2003.02846.x.
引用本文的文献
1
[Efficacy and safety of zanubrutinib in treating refractory/relapsed warm autoimmune hemolytic anemia].
Zhonghua Xue Ye Xue Za Zhi. 2025 Apr 14;46(4):355-358. doi: 10.3760/cma.j.cn121090-20241110-00442.
2
The Role of the Spleen and the Place of Splenectomy in Autoimmune Hemolytic Anemia-A Review of Current Knowledge.
Diagnostics (Basel). 2023 Sep 9;13(18):2891. doi: 10.3390/diagnostics13182891.
3
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
Eur J Haematol. 2022 Dec;109(6):719-727. doi: 10.1111/ejh.13858. Epub 2022 Sep 20.
4
Development of New Drugs for Autoimmune Hemolytic Anemia.
Pharmaceutics. 2022 May 11;14(5):1035. doi: 10.3390/pharmaceutics14051035.
5
Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.
J Clin Med. 2022 May 16;11(10):2807. doi: 10.3390/jcm11102807.
6
The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia.
J Clin Med. 2021 May 12;10(10):2064. doi: 10.3390/jcm10102064.
7
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.
Blood Adv. 2020 Mar 24;4(6):997-1005. doi: 10.1182/bloodadvances.2019001321.
8
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
J Clin Exp Hematop. 2018 Sep 19;58(3):136-140. doi: 10.3960/jslrt.18012. Epub 2018 Jul 14.
本文引用的文献
1
Mantle Cell Lymphoma.
J Clin Oncol. 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904. Epub 2016 Jan 11.
2
Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Leuk Lymphoma. 2016;57(3):735-7. doi: 10.3109/10428194.2015.1071489. Epub 2015 Oct 12.
3
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Br J Haematol. 2015 Sep;170(5):734-6. doi: 10.1111/bjh.13328. Epub 2015 Feb 25.
4
Mantle cell lymphoma: evolving management strategies.
Blood. 2015 Jan 1;125(1):48-55. doi: 10.1182/blood-2014-05-521898. Epub 2014 Dec 11.
5
Treatment of autoimmune hemolytic anemias.
Haematologica. 2014 Oct;99(10):1547-54. doi: 10.3324/haematol.2014.114561.
6
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25.
7
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.
8
Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis.
Leuk Lymphoma. 2009 Aug;50(8):1261-8. doi: 10.1080/10428190903026492.
Zotero 插件